14 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $701M | -$73M | 50.5% | -8.8% | $43M | $90M | $90M |
| 2024 | $688M | -$392M | 55.4% | -57.6% | $83M | $125M | $108M |
| 2023 | $673M | -$62M | 56.4% | 0.6% | $15M | $159M | $88M |
| 2022 | $684M | $51M | 57.6% | 5.2% | $72M | $226M | $128M |
| 2021 | $587M | $6M | 51.0% | -6.6% | $66M | $130M | $119M |
| 2020 | $715M | -$29M | 51.9% | -6.8% | -$23M | $180M | $112M |
| 2019 | $698M | -$46M | 57.7% | -8.0% | -$125M | $248M | $205M |
| 2018 | $652M | $58M | 59.9% | 0.1% | -$195M | $248M | $385M |
| 2017 | $612M | $79M | 55.1% | -7.0% | $101M | $581M | $220M |
| 2016 | $566M | $40M | 52.5% | -18.9% | $160M | $579M | $114M |
| 2015 | — | -$426M | — | — | $27M | $578M | $130M |
| 2014 | — | $27M | — | — | $69M | $627M | $149M |
| 2013 | — | $155M | — | — | $175M | $12M | $44M |
| 2012 | — | $153M | — | — | $162M | — | $48M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $182M | $5M | 51.7% | 4.9% | -$17M | $87M | $66M |
| Dec '25 | $181M | -$1M | 47.5% | 1.4% | $21M | $90M | $90M |
| Sep '25 | $178M | -$1M | 48.4% | 0.1% | $7M | $93M | $71M |
| Jun '25 | $175M | -$77M | 52.6% | -42.6% | -$4M | $96M | $90M |
| Mar '25 | $168M | $7M | 53.6% | 6.1% | $19M | $98M | $97M |
| Dec '24 | $180M | -$397M | 54.6% | -233.0% | $53M | $125M | $108M |
| Sep '24 | $170M | $4M | 54.5% | 7.0% | $20M | $153M | $89M |
| Jun '24 | $172M | $2M | 55.7% | 3.7% | $22M | $165M | $92M |
| Mar '24 | $166M | -$900000 | 57.1% | 2.4% | -$12M | $167M | $76M |
| Dec '23 | $173M | $11M | 54.8% | 6.5% | $7M | $159M | $88M |
| Sep '23 | $171M | -$4M | 55.8% | 0.7% | $25M | $258M | $107M |
| Jun '23 | $169M | -$68M | 57.7% | -1.2% | -$7M | $203M | $82M |
| Mar '23 | $159M | -$500000 | 57.4% | -3.8% | -$11M | $205M | $96M |
| Dec '22 | $182M | $17M | 56.7% | 9.1% | $29M | $226M | $128M |
| Sep '22 | $172M | $16M | 58.2% | 7.4% | $23M | $248M | $117M |
| Jun '22 | $171M | $13M | 59.4% | 5.9% | $23M | $249M | $107M |
| Mar '22 | $197M | $5M | 54.0% | 4.4% | -$3M | $254M | $104M |
| Dec '21 | $193M | $12M | 51.1% | 14.0% | $47M | $130M | $119M |
| Sep '21 | $184M | -$35M | 49.0% | 1.8% | $18M | $145M | $98M |
| Jun '21 | $186M | $39M | 46.0% | -3.9% | $10M | $165M | $100M |
How the market has priced AVNS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Avanos Medical, Inc.'s revenue has declined 0.4% per year. These are computed facts, not advice.
As of FY2025, Avanos Medical, Inc. reported $90M of total debt against $90M of cash; operating income covered interest expense -7.9×.
In FY2025, gross margin was 50.5%, operating margin -8.8%, and net margin -10.4%.
As of Jun '26, Avanos Medical, Inc. traded at a price-to-earnings ratio of about 20.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.